ERNA molecular marker for auxiliary diagnosis of Crohn disease and application of eRNA molecular marker

By detecting eRNA42767 in the plasma of patients with Crohn's disease, using fluorescence quantitative PCR technology, the problem of invasiveness and specificity of existing diagnostic methods is solved, the efficiency and accuracy of early diagnosis is achieved, and the Crohn's disease is improved. Detection rate.

CN119061137AInactive Publication Date: 2024-12-03NINGBO FIRST HOSPITAL

Patent Information

Application Number
CN202411570866.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-06
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing Crohn's disease diagnosis methods are highly invasive, lack specificity, and difficult to identify early molecular mechanisms. Traditional serological markers lack the ability to reflect changes in gene regulation networks, and imaging examinations are high, so they are not suitable for large-scale screening.

Method used

Develop a highly specific and highly sensitive eRNA molecular marker eRNA42767 and its application is used to assist in the diagnosis of Crohn's disease. Early diagnosis is achieved by detecting eRNA42767 in plasma, and fluorescence quantitative PCR technology is used to improve detection efficiency and accuracy.

Benefits of technology

By detecting eRNA42767 in the plasma of patients with Crohn's disease, the early diagnosis is highly targeted and sensitive, and the detection rate is improved, which is conducive to timely treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061137A_ABST
    Figure CN119061137A_ABST
Patent Text Reader

Abstract

The invention discloses an eRNA molecular marker for auxiliary diagnosis of Crohn's disease and application of the eRNA molecular marker, and is characterized in that the eRNA molecular marker is eRNA42767, and the nucleotide sequence of the eRNA molecular marker is shown as SEQ ID NO.1. The invention also provides application of the eRNA molecular marker in preparation of a kit for auxiliary diagnosis of Crohn's disease, and the kit comprises an eRNA42767 fluorescent quantitative PCR specific amplification primer, the nucleotide sequence of the upstream amplification primer is 5 '-CCTCTCTCTGGACATGCCTA-3', and the nucleotide sequence of the downstream amplification primer is 5 '-CCTATGCGTAGAGATTCTTGCC-3'. The kit has the advantages that early diagnosis of a patient suffering from the Crohn disease on the molecular level is conveniently, quickly and efficiently realized, the pertinence is strong, the specificity is strong, the sensitivity is high, and the kit is beneficial to early discovery and timely treatment of the Crohn disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an auxiliary diagnosis method for Crohn's disease, and in particular to an eRNA molecular marker for auxiliary diagnosis of Crohn's disease and application thereof. Background Art

[0002] Crohn's disease (CD) is one of the main entities in the spectrum of inflammatory bowel disease. It is a chronic inflammatory disease of the gastrointestinal tract that may lead to progressive intestinal damage and disability. The course of CD is characterized by its variability and unpredictability, and is associated with an increased long-term risk of colorectal cancer. The gold standard for the diagnosis of CD is colonoscopy and histological examination. The gold standard diagnostic method is highly invasive and may increase the risk of intestinal damage; traditional serological markers such as C-reactive protein and erythrocyte sedimentation rate lack specificity and are difficult to distinguish CD from other inflammatory bowel diseases; imaging examinations such as CT examinations and magnetic resonance imaging tests are expensive and not suitable for large-scale screening and frequent follow-up. Existing diagnostic methods mainly focus on changes in protein levels, lack understanding of the early molecular mechanisms of the disease, and lack diagnostic markers that can reflect changes in gene regulatory networks.

[0003] With the advancement of medical technology, the application of non-invasive monitoring methods in diagnosing and following up patients has increased rapidly. For example, by analyzing various omics data in patient-derived blood, new biomarkers can be provided, opening up new prospects for early diagnosis and disease prevention. Genome-wide association studies have discovered thousands of genetic variants that are associated with traits or change disease risk. These genes are mainly located in the non-coding genome, and the transcription of genes is affected by a variety of complex regulatory factors. Active enhancers have transcriptional potential and can generate non-coding transcripts defined as enhancer RNA (eRNA). eRNA has different functions in mediating gene expression through various transcriptional and post-transcriptional mechanisms. In recent years, studies have shown that eRNA exhibits potential biomarker effects in a variety of diseases, while the association between eRNA and CD has been less studied. eRNA has therapeutic potential in non-invasive detection in body fluids such as blood, saliva and urine. Therefore, it is of great significance to develop eRNA molecular markers for auxiliary diagnosis of Crohn's disease and to reflect the diagnosis of early molecular changes in CD disease. Summary of the invention

[0004] The technical problem to be solved by the present invention is to provide an eRNA molecular marker with strong specificity and high sensitivity for auxiliary diagnosis of Crohn's disease and its application.

[0005] The technical solution adopted by the present invention to solve the above technical problem is: an eRNA molecular marker for auxiliary diagnosis of Crohn's disease, the eRNA molecular marker is eRNA42767, and its nucleotide sequence is shown in SEQ ID NO. 1. The location is on human chromosome 2: 173644313-173653943.

[0006] The present invention also provides the use of the eRNA molecular marker in preparing a kit for auxiliary diagnosis of Crohn's disease.

[0007] The present invention also provides the use of the above-mentioned eRNA molecular marker in the preparation of a kit for auxiliary diagnosis of Crohn's disease, wherein the kit comprises upstream and downstream amplification primers of eRNA42767 fluorescent quantitative PCR, wherein the nucleotide sequence of the upstream amplification primer of eRNA42767 fluorescent quantitative PCR is as shown in SEQ ID NO.2: 5'-CCTCTCTCTGGGACATGCCTA-3'; the nucleotide sequence of the downstream amplification primer of eRNA42767 fluorescent quantitative PCR is as shown in SEQ ID NO.3: 5'-CACATGCGTAGAGATTCTTGCC-3'.

[0008] Compared with the prior art, the advantages of the present invention are: the present invention discloses for the first time an eRNA molecular marker for auxiliary diagnosis of Crohn's disease and its application, and the eRNA42767 molecular marker is highly expressed in the plasma of Crohn's disease patients. Using the collected peripheral blood specimens, the detection of eRNA42767 in the plasma can conveniently, quickly and efficiently diagnose Crohn's disease patients at the molecular level in an early stage, with strong pertinence, high sensitivity, and high accuracy of the test results, which improves the detection rate of Crohn's disease and is conducive to the early detection and timely treatment of Crohn's disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 Results of t-SNE (t-distributed stochastic neighbor embedding) analysis of tumor epithelial cells of 14 cancers (A) and log2 fold results of the average expression of eRNA in the colorectal cancer cell population relative to the average expression of all other cancer cell types (B); Figure 2 The agarose gel electrophoresis diagram of the amplified fragment of eRNA42767, including the complete sequence of the 5' end, the middle sequence and the complete sequence of the 3' end (A) and the schematic diagram of the design of specific upstream and downstream amplification primers for fluorescent quantitative PCR based on the eRNA42767 sequence (B); Figure 3 is the lg value of the pUC57-eRNA42767 recombinant plasmid copy number and C Linear standard curve of q value; Figure 4 Statistical analysis results of the eRNA42767 copy number in plasma of healthy people and Crohn's disease patients; Figure 5 ROC curve of eRNA42767 in the plasma of Crohn's disease patients. DETAILED DESCRIPTION

[0010] The present invention is further described in detail below with reference to the accompanying drawings.

[0011] Specific embodiment 1: Screening of eRNA molecular markers.

[0012] By collecting publicly available full-length single-cell sequencing databases including SMARTer, Smart-seq, Smart-seq2, Quartz-seq, RamDA-seq, SUPeR-seq, MATQ-seq and Tang's method, tumor epithelial cells of 14 cancers were collected, such as Figure 1 The specific examples are as follows: breast cancer subtypes (Luminal A, Luminal B), pancreatic adenocarcinoma (PAAD), oral squamous cell carcinoma (OSCC), triple-negative breast cancer (TNBC), myxoid liposarcoma (MLPS), HER2-positive breast cancer (Human epidermal growth factor receptor 2, HER2), glioblastoma multiforme (GBM), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), neuroblastoma (NB), multiple myeloma (MM), lung cancer (LC), and colorectal cancer (CC).

[0013] We further established a human eRNA collection based on enhancer databases such as ENCODE, FANTOM, and Roadmap, and eRNA databases such as HeRA, eRic, HACER, and RAEdb. We then used the findallmarker function in the Seurat package in the R language to calculate and identify the characteristic genes of specific cell populations, and calculated the corresponding specifically expressed marker eRNAs in tumor epithelial cells of 14 cancers (the average expression of eRNA in a specified cell type relative to the average expression of all other cell types log2 times>0.5), such as Figure 1 As shown in A, the t-SNE (t-distributed stochastic neighbor embedding) analysis results of tumor epithelial cells of 14 types of cancer are displayed, and different colors represent different cancer types.

[0014] like Figure 1 As shown in B, the characteristic eRNA of the colorectal cancer cell population is calculated by the findallmarker function. The average expression level of eRNA42767 in the colorectal cancer cell population is log2 times greater than 0.5 relative to the average expression level of all other cancer cell types, and eRNA42767 is screened out as one of the marker eRNAs in the colorectal cancer cell population. Figure 1 The circle color gradient in B represents the average expression level of eRNA, and the circle size gradient represents the percentage of cells expressing characteristic eRNA in the colon cancer cell population to the total number of cells of this tumor type.

[0015] Specific embodiment 2: Diagnostic validation of eRNA molecular markers.

[0016] 1. Data collection of Crohn's disease patients: This study collected 60 Crohn's disease patients and 77 plasma samples from healthy people from the First Affiliated Hospital of Ningbo University. Informed consent was obtained from the patients or their families. Among them, 35 healthy people were male and 41 were female, with an average age of (38.7±9.8) years old; 42 Crohn's disease patients were male and 19 were female, with an average age of (39.8±11.6) years old. The patient-related information was complete and a clinical data database was established in accordance with regulations.

[0017] Inclusion criteria: (1) patients diagnosed with Crohn's disease by endoscopic examination, histopathological evidence, etc.; (2) patients in the active stage of the disease (moderate to severe); (3) age range 18 to 75 years. Exclusion criteria: (1) patients with other types of inflammatory bowel disease such as ulcerative colitis; (2) patients with serious complications such as intestinal perforation, abdominal abscess, severe infection; (3) patients currently using immunosuppressants, corticosteroids and other drugs; (4) patients with severe diseases such as severe liver or kidney damage, cardiovascular disease, etc.; (5) patients who had undergone intestinal surgery within 3 to 6 months before the study.

[0018] 2. Separation of plasma: Draw 5 mL of peripheral blood into an EDTA anticoagulated blood collection tube, immediately place it in a 4°C refrigerator, let it stand for 30 minutes, centrifuge it at 3000 rpm for 10 minutes at 4°C to remove the residual blood cell components in the plasma, aspirate the upper plasma, transfer it to an enzyme-free centrifuge tube, divide the obtained plasma samples into aliquots, and freeze them in a -80°C refrigerator.

[0019] 3. Extraction of plasma RNA: Use Trizol LS reagent from Invitrogen, USA, pipette 250 μL of plasma sample into a 1.5 mL nuclease-free centrifuge tube, add 750 μL of Trizol LS reagent, fasten the cap of the centrifuge tube, vortex for 15 seconds, and place in a 4°C refrigerator for 10 minutes; take it out and centrifuge it for 10 seconds, add 200 μL of chloroform, fasten the cap of the centrifuge tube, shake it by hand 6 times, place it in a 4°C centrifuge for 3 minutes, and centrifuge it at 4°C, 12000 rpm for 15 minutes to separate the liquid in the tube into 3 clear layers; prepare a 1.5 mL nuclease-free centrifuge tube, add 500 μL of isopropanol, take out the centrifuged specimen, pipette 500 μL of the upper transparent liquid into the prepared centrifuge tube with isopropanol, fasten the cap of the centrifuge tube, invert and mix, let it stand at 4°C for 10 minutes, and then centrifuge it at 4°C, 12000 rpm for 10 min, carefully discard the supernatant; add 1 mL of pre-cooled 75% ethanol to the centrifuge tube, fasten the centrifuge tube cap, and turn the centrifuge tube upside down to wash the precipitate; centrifuge at 4°C, 12000 rpm for 3 min, discard the supernatant, and place the centrifuge tube in the centrifuge again, centrifuge at 4°C, 12000 rpm for 1 min and discard the supernatant; dry for 3 min, add 8 μL of enzyme-free water, and mix by pipetting; take 8 μL of total RNA for reverse transcription.

[0020] 4. Synthesize cDNA: According to the instructions of Polestar 1st cDNA Synthesis Kit (gDNA removal) produced by Beijing Baoying Tonghui Biotechnology Co., Ltd., prepare the reverse transcription reaction solution according to the following component formula: Reverse transcription reaction system: 7 µL enzyme-free water, 4 µL 5×Polestar RT MasterMix (with dsDNase), 20 μM concentration of OligodT (18) 1 µL, total RNA 8 µL, total volume 20 µL. cDNA synthesis reaction program: 25℃ 10min, 55℃ 60 min, 85℃ 5min, reverse transcribed cDNA stored at -20℃, if you directly proceed to the next step of fluorescent quantitative PCR experiment, add samples according to the PCR system.

[0021] 5. Rapid amplification of cDNA ends (RACE) was used to determine the true full length of eRNA42767, whose nucleotide sequence is shown in SEQ ID NO.1. The specific process is as follows: RNA was extracted using Trizol extraction kit (purchased from Shanghai Sangon Biotechnology, catalog number B511321), 1.5% agarose, 1× Tris-acetate electrophoresis buffer, and observed and photographed under ultraviolet transmission light. The 5'-RACE kit was purchased from Shanghai Sangon Biotechnology (catalog number B605102), the nucleotide sequence of the upstream primer for 5'-RACE specific amplification is shown in SEQ ID NO.4: 5'-CTCATTAGATATACAGAATCCTTCACAG-3', and the nucleotide sequence of the downstream primer for 5'-RACE specific amplification is shown in SEQ ID NO.5: 5'- CCTTGTCCATCATGATCACTCAAC-3'.

[0022] The 3'-RACE kit was purchased from Shanghai Sangon Biotechnology (Cat. No. B605101). The nucleotide sequence of the upstream primer for 3'-RACE specific amplification is shown in SEQ ID NO.6: 5'-GCATACTATTCTGTGGCATATATGTAC-3', and the nucleotide sequence of the downstream primer for 3'-RACE specific amplification is shown in SEQ ID NO.7: 5'-TACACCAAGGTGCTTCATCATTC-3'.

[0023] The nucleotide sequence of the upstream primer of the eRNA42767 intermediate sequence fragment 1 (PCR amplification product length 5192 bp) is shown in SEQ ID NO.8: 5'-CATATCTACTCTTACCAAGGTCTGAAA-3', and the nucleotide sequence of the downstream primer is shown in SEQ ID NO.9: 5'-CCTTCATTTAAGCCTCCATCTCTA-3'.

[0024] The nucleotide sequence of the upstream primer of the eRNA42767 intermediate sequence fragment 2 (PCR amplification product length is 3096bp) is shown in SEQ ID NO.10: 5'-GGGAGGAGAGAGAAAAAGAAAATAGA-3', and the nucleotide sequence of its downstream primer is shown in SEQ ID NO.11: 5'-GCAACCCATACATGGTAATTCTCA-3'. These two intermediate sequences have overlapping sequences and can cover the sequence of the entire intermediate region.

[0025] The results are as follows Figure 2As shown in A, agarose gel electrophoresis clearly shows the amplified fragment, including the complete sequence of the 5' end, the middle sequence and the complete sequence of the 3' end. The cDNA end rapid amplification technology proves that the complete sequence of the 5' end of eRNA42767 is 444bp, and the complete sequence of the 3' end is 1793bp. The upstream and downstream amplification primers of eRNA42767 fluorescence quantitative PCR were further designed, as shown in FIG. Figure 2 As shown in B, upstream and downstream amplification primers of the fluorescence quantitative PCR were designed at the 8384-8514bp position of the eRNA42767 sequence. The nucleotide sequence of the upstream amplification primer of the eRNA42767 fluorescence quantitative PCR is shown in SEQ ID NO.2: 5'-CCTCTCTCTGGGACATGCCTA-3'; the nucleotide sequence of the downstream amplification primer of the eRNA42767 fluorescence quantitative PCR is shown in SEQ ID NO.3: 5'-CACATGCGTAGAGATTCTTGCC-3'. The PCR product length was measured by TA cloning sequencing to be 131bp, and matched the sequence at 8384-8514bp of eRNA42767, proving that the designed upstream and downstream amplification primers are specific.

[0026] 6. Preparation of plasmid standards: After TA cloning and sequencing of the PCR product of eRNA42767, the base sequence 131bp obtained by sequencing was cloned into the pUC57 plasmid to obtain the pUC57-eRNA42767 recombinant plasmid (inserted base 131bp, full length of the plasmid 2835bp), which was prepared by General Biotechnology (Anhui) Co., Ltd.

[0027] 7. UV spectrophotometer measurement of recombinant plasmid: Dissolve pUC57-eRNA42767 recombinant plasmid powder in 50 μl of enzyme-free water to obtain the first high-concentration standard, and then measure its concentration and OD 260 The concentration of the recombinant plasmid pUC57-eRNA42767 was 219.31 ng / μL, and the OD 260 The value is 4.386.

[0028] 8. Absolute quantitative PCR: The high-concentration standard was diluted in gradients, and the copy number in 1 μL of plasmid standard was calculated according to the formula, where the DNA length is the full length of the plasmid, including the backbone vector. The copy number of the pUC57-eRNA42767 recombinant plasmid in 8 dilution gradients was calculated, and the concentrations were 7.06×10 9 copies / μL, 7.06×10 8 copies / μL, 7.06×10 7 copies / μL, 7.06×10 6copies / μL, 7.06×10 5 copies / μL, 7.06×10 4 copies / μL, 7.06×10 3 copies / μL and 7.06×10 2 Each gradient of plasmid standard was set up with 3 replicates, and the samples were added to the 96-well PCR reaction plate. Amplification was performed according to the reaction system and reaction procedure of real-time quantitative PCR amplification to obtain 8 different copy numbers. C q value.

[0029] The reaction system formula of real-time quantitative PCR amplification is as follows: 10.9 µL enzyme-free water, 1 µL cDNA, 0.3 µL 10 µM upstream amplification primer of fluorescence quantitative PCR, 0.3 µL 10 µM downstream amplification primer of fluorescence quantitative PCR, 12.5 µL GoTaq®qPCR Master Mix 2×, total volume is 25 µL. The reaction program of real-time quantitative PCR amplification is as follows: 95°C pre-denaturation for 5 minutes, 1 cycle; 95°C denaturation for 15 seconds, 62°C annealing for 30 seconds, 72°C extension for 30 seconds, 40 cycles. The fluorescence quantitative PCR determination system automatically generates the standard curve of the pUC57-eRNA42767 recombinant plasmid according to the change law of fluorescence value.

[0030] The results are as follows Figure 3 As shown, the linear equation of the pUC57-eRNA42767 recombinant plasmid is Y = -3.804X + 46.06, where Y is the value obtained by real-time quantitative PCR detection. C q value, 10 X The corresponding copy number in the test sample. The determination coefficient R 2 is 0.9957, indicating that within the range of plasmid dilution concentration, the lg value of the pUC57-eRNA42767 recombinant plasmid copy number is C The q value has a good linear relationship. The amplification efficiency E is 83.18%, indicating that the standard curve established by each recombinant plasmid can accurately reflect the amplification of the target product.

[0031] The absolute quantitative PCR was used to obtain the C The q value, i.e. the Y value in the formula, is calculated according to the formula Y = -3.804X +46.06, and the copy number of eRNA42767 in 1 μL cDNA is 10 XSince 8 μL RNA was extracted from 250 μL plasma, and then all 8 μL RNA was used for reverse transcription to obtain 20 μL cDNA, and only 1 μL cDNA was used for real-time quantitative PCR amplification, it was inferred that the copy number of eRNA42767 in 1 mL plasma was 80×10 X Calculation. The copy number of eRNA42767 in 1 mL of plasma from healthy people and Crohn's disease patients was statistically analyzed. The results are as follows Figure 4 As shown, eRNA42767 was significantly highly expressed in the plasma of Crohn's disease patients, and the cutoff value for distinguishing healthy people from Crohn's patients was 431,550 copies / mL.

[0032] 9. Use ROC curve to analyze the diagnostic ability of eRNA42767 molecular marker: According to the level of eRNA42767 in the plasma of healthy people and Crohn's patients, analyze the area under the ROC curve, sensitivity, specificity, positive predictive value and negative predictive value of eRNA42767 level in distinguishing healthy people from Crohn's patients, and evaluate the diagnostic value of eRNA42767 in judging Crohn's patients. Figure 5 As shown, the diagnostic value of eRNA42767 in Crohn's disease plasma is: the area under the ROC curve is 0.862, the sensitivity is 0.817, the specificity is 0.805, the positive predictive value is 0.766, and the negative predictive value is 0.849, which can be effectively used for the early diagnosis of Crohn's disease.

[0033] The above description is not intended to limit the present invention, and the present invention is not limited to the above examples. Any changes, modifications, additions or substitutions made by a person skilled in the art within the spirit and scope of the present invention shall also fall within the protection scope of the present invention.

Claims

1. An eRNA molecular marker for assisting the diagnosis of Crohn's disease, characterized in that: The eRNA molecular marker is eRNA42767, and the eRNA42767 nucleotide sequence is shown in SEQ ID NO.

1.

2. Use of the eRNA molecular marker according to claim 1 in preparing a kit for auxiliary diagnosis of Crohn's disease.

3. Use of an eRNA molecular marker according to claim 2 in preparing a kit for auxiliary diagnosis of Crohn's disease, characterized in that: The kit includes upstream and downstream amplification primers for eRNA42767 fluorescence quantitative PCR. The nucleotide sequence of the upstream amplification primer of eRNA42767 fluorescence quantitative PCR is shown in SEQ ID NO.2: 5'-CCTCTCTCTGGGACATGCCTA-3', and the nucleotide sequence of the downstream amplification primer of eRNA42767 fluorescence quantitative PCR is shown in SEQ ID NO.3: 5'-CACATGCGTAGAGATTCTTGCC-3'.

Citation Information

Patent Citations

  • miRNA markers associated with Crohn disease and application thereof

    CN108796066A

  • Circular RNA marker for detecting Crohn's disease and application

    CN111733226A

  • Long non-coding rnas (lncrnas) for the diagnosis and therapeutics of brain disorders, in particular cognitive disorders

    CN113286895A

  • Application of enhancer RNA (Ribonucleic Acid) as target spot in preparation of medicine for preventing or treating inflammatory bowel disease

    CN116555258A

  • Biomarker compositions and methods

    WO2014082083A1

Cited By

  • Composition for diagnosing Crohn disease, kit and application of enhancer RNA44345 in preparation of composition

    CN120174078A

  • Application of reagent for detecting tsRNA molecular marker in intestinal mucosa tissue in preparation of Crohn disease diagnostic kit

    CN121896348A